Compare NRK & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | ATXS |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.5M | 722.1M |
| IPO Year | N/A | 2015 |
| Metric | NRK | ATXS |
|---|---|---|
| Price | $9.98 | $12.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 187.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.95 | $3.56 |
| 52 Week High | $11.09 | $13.29 |
| Indicator | NRK | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.16 | 65.69 |
| Support Level | $10.03 | $12.70 |
| Resistance Level | $10.15 | $13.29 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 5.37 | 67.84 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.